Skip to main content
. 2023 Jun 19;195(24):E833–E843. doi: 10.1503/cmaj.220960

Table 2:

Study characteristics

First author and year of publication Study type No. of participants Intervention Follow-up period Age, yr, mean Male, % Risk of PE
Fasullo 201126 RCT 72 tPA v. UFH 6 mo 56.0 56.9 Intermediate-high
D’Auria 202027 Cohort 198 CDT v. AC 2 yr 58.5 52.0 Intermediate
Schissler 201828 Cohort 104 USAT v. AC 6 mo 55.6 44.2 Intermediate
Meyer 201429 RCT 1005 TNK v. UFH 30 d 66.1 47.0 Intermediate-high
Beyer 202030 Cohort 5436 CDT/USAT v. ST 30 d 59.5 50.9 High: 11.2%
Unclear: 88.8%
Dotter 197931 RCT 31 SK v. UFH 7 d 59.5 38.7 Intermediate or high
Avgerinos 201632 Cohort 128 CDT/USAT v. AC 14 d 59.3 49.2 Intermediate-high
Klevanets 201733 Cohort 209 CDT v. ST 6 mo 56.0 52.6 High
Macovei 201534 RCT 52 IAT v. SK NA 54.9 44.2 High
Sharifi 201935 Cohort 97 USAT v. HDT 30 d 60.0 57.7 High: 14.4%
Intermediate-high: 85.6%
Jerjes-Sanchez 199536 RCT 8 SK v. UFH 1–3 d 62.5 63.0 High
Blackmon 197037 RCT 160 UK v. UFH 14 d ≥ 50.0 57.3 Intermediate or high
Stein 199038 RCT 13 tPA v. UFH 7 d 55.6 58.5 Unclear
Yoo 201639 Cohort 72 CDT v. ST 10 d 63.9 30.6 High: 50%
Intermediate: 50%
Hamel 200140 Cohort 128 ST v. AC 3 yr 72.0 31.0 High
Liang 201741 Cohort 2860 CDT v. ST 3 yr 56.0 55.0 High: 11.3%
Intermediate: 88.7%
Tibbutt 197442 RCT 30 SK v. UFH 6 mo 48.7 50.0 Intermediate or high
Ahmed 201843 RCT 52 ST v. AC NA 44.7 46.1 Intermediate-high
Ly 197844 RCT 25 SK v. UFH 30 d 53.2 44.0 Intermediate or high
Miller 197145 RCT 23 SK v. UFH 3 d 50.5 34.8 High
Kucher 201446 RCT 59 USAT v. UFH 90 d 63.0 47.0 Intermediate
Arora 201747 Cohort 3384 CDT v. ST 30 d 50–79 52.1 Unclear
Avgerinos 201848 Cohort 317 CDT v. ST 30 d 58.8 47.9 High: 28.4%
Intermediate: 71.6%
Goldhaber 199349 RCT 101 tPA v. UFH 14 d 58.5 43.5 Intermediate: 45.5%
Unclear: 55.5%
Zhang 201850 RCT 66 rt-PA v. LMWH 90 d 59.5 48.5 Intermediate
Sista 201851 Cohort 85 ST v. AC v. CDT NA 65.0 50.6 High: 9%
Intermediate: 91%
Dalla-Volta 199252 RCT 36 tPA v. UFH 30 d 64.7 33.0 Unclear
Sharifi 201353 RCT 121 tPA v. UFH/LMWH 840 d 58.5 45.5 Intermediate
Konstantinides 200254 RCT 256 tPA v. UFH 30 d 62.1 47.6 Intermediate
Lee 202055 Cohort 820 ST v. AC 3 mo 64.2 46.5 High
Stein 202056 Cohort 1830 CDT v. AC 90 d 60.0 58.5 Intermediate
Rehman 202057 Case–control 86 ST v. AC 30 d 59.9 61.6 Intermediate-high
Bradley 202258 Cohort 63 tPA v. UFH v. CDT NA 55.4 57.1 Intermediate-high
Gorgis 202259 Cohort 384 USAT v. AC 12 mo 59.3 49.0 Intermediate-high
Harrison 202160 Cohort 34 CDT v. AC NA 75.7 NA Intermediate-high
Kline 202161 Cohort 130 USAT v. AC NA 63.0 43.8 Intermediate
Kroupa 202262 RCT 23 CDT v. AC 30 d 62.0 56.5 Intermediate-high
Lin 202163 Cohort 1303 CDT v. ST 3.4 yr 62.7 44.7 Unclear
Patel 201564 Cohort 868 CDT v. ST Unclear 58.0 37.0 Unclear
Sadeghipour 202265 RCT 94 CDT v. AC 3 mo 58.4 71.0 Intermediate-high
Weng 202166 Cohort 81 Low-dose UK v. LMWH Unclear 65.6 43.2 Intermediate-high
Yilmaz 202167 Cohort 76 Half-dose rt-PA v. LMWH 6 mo 66.0 46.1 Intermediate
Zimmermann 202268 Cohort 55 ST v. AC 1 yr 62.0 68.1 Intermediate-high
Geller 202069 Cohort 1258 CDT v. ST 1 yr 57.4 54.7 Unclear

Note: AC = anticoagulation, CDT = catheter-directed thrombolysis, HDT = systemically administered half-dose thrombolysis, IAT = intra-arterial thrombolysis, LMWH = low-molecular-weight heparin, NA = not available, PE = pulmonary embolism, RCT = randomized controlled trial, rt-PA = recombinant tissue plasminogen activator, SK = streptokinase, ST = systemic thrombolysis, TNK = tenecteplase, tPA = tissue plasminogen activator, UFH = unfractionated heparin, UK = urokinase, USAT = ultrasound-assisted catheter-directed thrombolysis.